The addition of trastuzumab, an antibody inhibitor of human epidermal growth factor receptor 2 (HER-2), to pembrolizumab and chemotherapy in the treatment of HER-2-positive gastric cancer also markedly reduced the tumor size and significantly improved the objective response rate (22). Here, ERBB2 is linked to neoplasm.